Protara Therapeutics (TARA) Change in Account Payables (2019 - 2026)

Protara Therapeutics' Change in Account Payables history runs 8 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• In Q1 2026, Change in Account Payables rose 172.41% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.7 million (up 28.45% YoY), while the FY2025 annual figure was -$873000.0, down 163.22% from the prior year.
• Change in Account Payables was $1.1 million for Q1 2026 at Protara Therapeutics, up from -$1.6 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $3.0 million in Q2 2025 to a low of -$2.2 million in Q2 2023.
• Historically, Change in Account Payables has averaged $180941.2 across 5 years, with a median of $64000.0 in 2022.
• The sharpest annual moves came in 2022 and 2023: Change in Account Payables soared 4242.31% in 2022, then sank 1395.97% in 2023.
• A 5-year view of Change in Account Payables shows it stood at $1.1 million in 2022, then plunged by 106.2% to -$70000.0 in 2023, then surged by 2271.43% to $1.5 million in 2024, then sank by 202.76% to -$1.6 million in 2025, then surged by 169.72% to $1.1 million in 2026.
• The last three Change in Account Payables figures came in at $1.1 million (Q1 2026), -$1.6 million (Q4 2025), and -$795000.0 (Q3 2025), per Business Quant data.